MYNZEPLI 40 mg/ml sol inj 2 mg 1 pce

7680706180010 CH-70618 S01LA05 11.99.0.

Active substances:

Afliberceptum

No images available

Details

Product number
7061801
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
afliberceptum 2 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 0.05 ml.

Articles (1)

Mynzepli 40 mg/ml, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
afliberceptum
2.0 MG Substance Wirkstoff (Principe actif)
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
trehalosum dihydricum
- Substance HNIDK
poloxamerum 188
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 478.45
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/08/2026

Authorization holder

Advanz Pharma Specialty Medicine

8048 Zürich

Authorization information

Swissmedic authorization number
70618
Drug name
Mynzepli, Injektionslösung
Galenic form
LSINJ
ATC Code
S01LA05
Authorization status
Z
Dispensation category
B
First authorization
13/05/2026
Authorization expiration date
12/05/2031
IT number
11.99.0.
Domain
Human medicine
Field of application
Exsudative (feuchte) altersbezogene Makuladegeneration (AMD). Makulaödem infolge eines retinalen Zentralvenenverschlusses (CRVO) und retinalen Venenastverschlusses (BRVO), diabetisches Makulaödem (DME), Behandlung von subfovealen und juxtafovealen choroidalen Neovaskularisationen infolge einer pathologischen Myopie (mCNV).

Packaging details

Description (FR)
MYNZEPLI 40 mg/ml sol inj 2 mg 1 pce
Description (DE)
MYNZEPLI 40 mg/ml Inj Lös 2 mg 1 Stk
Market launch
01/08/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data